Research & Studies

At bioMONTR Labs, we believe in nurturing and re-investing in the scientific community. As a key opinion leader laboratory, we take the opportunity to publish and present the exciting results from many of our assay development efforts. Summaries are provided below for a few of our recent publications/presentations. Contact us if you are interested in learning more.
Cerebrospinal fluid CXCL10 is associated with the presence of low-level CSF HIV during suppressive antiretroviral therapy
(Journal of Neuroimmunology 2021, 353:577493) Cerebrospinal fluid CXCL10 is associated with the presence of low-level CSF HIV during suppressive antiretroviral therapy.
Low-Level HIV RNA in Cerebrospinal Fluid and Neurocognitive Performance: A Longitudinal Cohort Study
(JAIDS 2021, 87(5):1196-1204) Low-Level HIV RNA in Cerebrospinal Fluid and Neurocognitive Performance: A Longitudinal Cohort Study
Increasing the performance of a fully automated quantitative assay for the detection of circulating HBV pregenomic RNA
(presented at 2021 HEP DART in Los Cabos, Mexico) Summary: A presentation of the increased analytical performance of a fully automated assay for the detection and quantitation of hepatitis B pregenomic RNA in CHB patients.
Hepatitis B pregenomic RNA: Performance of an Automated Real-Time Quantitative Assay
(presented at 2019 CVS in Savannah, GA) Summary: A presentation of the analytical performance of a new assay for the detection and quantitation of hepatitis B pregenomic RNA in CHB patients.
Prevelence and Correlates of Persistent HIV-1 RNA in Cerebrospinal Fluid During Antiretroviral Therapy
(The Journal of Infectious Diseases 2017, 215:105-13) Summary: bioMONTR Labs’ proprietary HIV-1 SuperLow Assay was utilized to measure HIV-1 RNA levels in CSF and plasma from adults taking suppressive ART to assess if the association between HIV-1 RNA discordance and HAND may reflect compartmentalization.
Validation of eMAG™ for HIV-1 Low Viremia Testing
(Presented at 2017 CVS in Savannah, GA) Summary: A presentation of the validation for using the eMAG with bioMONTR Labs’ HIV-1 SuperLow assay, a RESEARCH USE ONLY for detection of single copy HIV-1 RNA.